ACUTE BIPHENOTYPIC LEUKEMIA

This study tests whether removing a specific type of immune cell (naive T cells) from donated stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body, causing long-term…

This study tests a combination of two drugs, enasidenib and azacitidine, for people with a specific genetic form of acute myeloid leukemia (IDH2-mutated) that has come back or stopped responding to treatment. The goal is to see if the combo can shrink or control the cancer. About…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…

This study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…

This early-phase study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. About 12 patients will receive either strong or milder chemotherapy before the transplant. Researchers will monit…

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…